In the murine breast cancer model, palbociclib was also shown to reduce the PD-L1 expression and increase the tumor cell production of CXCL10 and CXCL13 chemokines, thereby increasing lymphocyte recruitment to the TME [104,105]. Here, CD274 is linked to breast cancer.